fda glp-1 warning letters september 2025 Beyond the Headlines: to Compounders Trends In FDA FY 2025

This research points to a potentially new pharmacological treatment paradigm for alcohol use disorder, which could yield enormous benefits for society. Carel W

Unlimited check-ins : Patients can consult their healthcare team anytime to manage side effects like nausea or constipation or to adjust their treatment plan

Due to the increase in use, science may need time to catch up on the side effects as in, to determine both short-term and long-term side effects as the drugs are used for different conditions and for longer periods of time

Wong MH, Oelkers P, Dawson PA

Biochem Biophys Res Commun 159(2):741747 Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV et al (2011) Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2022) performed a retrospective analysis using EHR data to examine the prevalence of AUD diagnoses in individuals prescribed GLP-1RAs for type 2 diabetes